X
    學術可視化工作室RC   登錄   提交文稿
學術英文編修

Oncologie

期刊標題檢索 ONCOLOGIE 最新評論: Should I submit in PDF format or LaTeX format? (2024-05-05)


期刊名稱:   ISSN:   主題領域:   影響因子範圍: -
索引:   類別:   開放訪問:   排序方式:

[Oncologie]您好,您是該頁面的第 23999 位訪客。

期刊簡介
期刊名稱Oncologie Oncologie
LetPub Score
4.9
50 ratings
Rate

Reputation
6.4

Influence
3.3

Speed
7.0

期刊簡稱ONCOLOGIE
ISSN1292-3818
E-ISSN1765-2839
h-index9
CiteScore
CiteScoreSJRSNIPCiteScore Rank
1.300.2690.269
Subject fieldQuartilesRankPercentile
Category: Medicine
Subcategory: Oncology
Q3299 / 404

自引率 (2023-2024)7.10%自引率趨勢
掲載範囲
Oncologie is aimed to the publication of high quality original research articles, review papers, case report, etc. with an active interest in vivo or vitro study of cancer biology. Study relating to the pathology, diagnosis, and advanced treatment of all types of cancers, as well as research from any of the disciplines related to this field of interest. The journal has English and French bilingual publication.
官方網站https://www.techscience.com/journal/oncologie
在線稿件提交http://www.tspsubmission.com/index.php/oncologie/about/submissions
開放訪問No
出版商Tech Science Press
主題領域医学
出版國/地區FRANCE
發行頻率隔月刊行
創刊年2004
每年文章數78每年文章數趨勢
黃金OA百分比78.57%
Web of Science 四分位
2023-2024
WOS Quartile: Q4

CategoryEditionJIF QuartileJIF RankingJIF Percentage
ONCOLOGYSCIEQ4263/322
索引 (SCI or SCIE)Science Citation Index Expanded
鏈接到PubMed Central (PMC)https://www.ncbi.nlm.nih.gov/nlmcatalog?term=1292-3818%5BISSN%5D
平均審稿時間 *來自出版商的數據:
來自作者的數據: Slow, 6-12 Week(s)
競爭力 *來自作者的數據: Easy
參考鏈接
相關期刊 【Oncologie】CiteScore趨勢
自引率趨勢 每年文章數趨勢
作者評論
*所有的審稿過程指標,如接受率和審稿速度,僅限於用戶提交的稿件。因此,這些指標可能無法準確反映期刊的競爭力或速度。
  • 同一學科的期刊
  • CiteScore趨勢
  • 自引率趨勢
  • 每年文章數趨勢
  •  
    學科內的可信期刊 影響因子
    CA-A CANCER JOURNAL FOR CLINICIANSH-index: 144

    CiteScore: 873.20
    Nature Reviews Clinical OncologyH-index: 127

    CiteScore: 99.40
    NATURE REVIEWS CANCERH-index: 396

    CiteScore: 111.90
    ANNALS OF ONCOLOGYH-index: 210

    CiteScore: 63.90
    CANCER CELLH-index: 295

    CiteScore: 55.20
    JOURNAL OF CLINICAL ONCOLOGYH-index: 494

    CiteScore: 41.20
    LANCET ONCOLOGYH-index: 274

    CiteScore: 62.10
    CANCER RESEARCHH-index: 411

    CiteScore: 16.10
    SEMINARS IN CANCER BIOLOGYH-index: 134

    CiteScore: 26.80
    JOURNAL OF EXPERIMENTAL & CLINICAL CANCER RESEARCHH-index: 67

    CiteScore: 18.20
    學科內最受檢索的期刊 頁面查看次數
    CANCER LETTERS326091
    CANCER RESEARCH310905
    BMC CANCER242777
    JOURNAL OF EXPERIMENTAL & CLINICAL CANCER RESEARCH197870
    INTERNATIONAL JOURNAL OF CANCER188165
    Asian Pacific Journal of Cancer Prevention184122
    CLINICAL CANCER RESEARCH180931
    JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY171551
    ONCOLOGY REPORTS171142
    CA-A CANCER JOURNAL FOR CLINICIANS163239
  •  

    Oncologie Oncologie
    明年預測:
    穩步上升 無變化 逐步下降  刷新
  •  

     
  •  

     


首頁    上一頁    1    2    下一頁    末頁  (頁
/2)
  [Oncologie] 的評論撰寫評論
作者: 黄土佳沫


領域: 医学
審稿時間: 0.0 month(s)
結果: 待定&不明


撰寫評論

2024-05-05 14:16:37 評論於
Should I submit in PDF format or LaTeX format?
(0) 讚! | 黄土佳沫

作者: doctor su


領域: 医学
審稿時間: 0.0 month(s)
結果: 待定&不明


撰寫評論

2024-04-22 17:11:46 評論於
Overall, this magazine is pretty good, but there is a high percentage of Chinese authors, which could have potential risks
(0) 讚! | doctor su

作者: doctor su


領域: 医学
審稿時間: 0.0 month(s)
結果: 待定&不明


撰寫評論

2024-04-22 17:09:05 評論於
Overall, this magazine is pretty good, but the proportion of Chinese authors is too high. I wonder if there is a risk of lack of diversity
(0) 讚! | doctor su

作者: doctor su


領域: 医学
審稿時間: 0.0 month(s)
結果: 待定&不明


撰寫評論

2024-04-22 17:07:49 評論於
This magazine looks good. The impact factor should exceed 1 this year, but I feel there is a risk. Not sure if the high proportion of Chinese authors will trigger a warning
(0) 讚! | doctor su

作者: 东海梦雁


領域: 医学
審稿時間: 0.0 month(s)
結果: 待定&不明


撰寫評論

2024-03-12 17:33:25 評論於
Review speed: 1.0 | Acceptance rate: 75.0
Experience sharing: The journal review speed is quite fast, and it was accepted in a little over a month. The reviewers' comments were very professional. Hopefully, the impact factor will increase again
(0) 讚! | 东海梦雁

作者: 通幽其倩


領域: 医学
審稿時間: 0.0 month(s)
結果: 待定&不明


撰寫評論

2024-02-27 17:24:25 評論於
Desperately seeking EndNote format! Or which format is easier to modify?
(0) 讚! | 通幽其倩

作者: 杨家梦森


領域: 医学
審稿時間: 0.0 month(s)
結果: 待定&不明


撰寫評論

2024-02-06 21:26:51 評論於
You
(0) 讚! | 杨家梦森

作者: 白云向阳


領域: 医学
審稿時間: 0.0 month(s)
結果: 待定&不明


撰寫評論

2024-01-27 21:20:16 評論於
At that time, we were still using the old system, there was no specific review status, and we received a revised email a month later
(0) 讚! | 白云向阳

作者: 白云向阳


領域: 医学
審稿時間: 0.0 month(s)
結果: 待定&不明


撰寫評論

2024-01-27 15:28:09 評論於
There is no specific format for Endnote, so I had to adjust them one by one based on a similar one I found
(0) 讚! | 白云向阳

作者: 岭南雅柔


領域: 医学
審稿時間: 0.0 month(s)
結果: 待定&不明


撰寫評論

2023-12-06 21:45:58 評論於
Hello, what is the specific reference format? I couldn't find the same in Endnote
(0) 讚! | 岭南雅柔

作者: 岭南雅柔


領域: 医学
審稿時間: 0.0 month(s)
結果: 待定&不明


撰寫評論

2023-12-06 10:26:48 評論於
What is the format of the reference list? I couldn't find the document package on the official website ?
(0) 讚! | 岭南雅柔

作者: 岭南雅柔


領域: 医学
審稿時間: 0.0 month(s)
結果: 待定&不明


撰寫評論

2023-12-06 10:19:48 評論於
Hello, what format is the specific reference in? I can't find this journal in Endnote
(0) 讚! | 岭南雅柔

作者: 岭南睿聪


領域: 医学
審稿時間: 0.0 month(s)
結果: 待定&不明


撰寫評論

2023-10-30 13:23:58 評論於
When is the first decision going to be made? Will the external review have a clear status?
(0) 讚! | 岭南睿聪

作者: Julia Coverdale


領域: 医学
審稿時間: 0.0 month(s)
結果: 待定&不明


撰寫評論

2023-10-28 21:09:08 評論於
How can I find the submission guidelines for a magazine?
(0) 讚! | Julia Coverdale

作者: 是志丹吖


領域: 医学
審稿時間: 0.0 month(s)
結果: 待定&不明


撰寫評論

2023-10-28 20:42:24 評論於
The submission information in the left menu contains a homepage
(0) 讚! | 是志丹吖

作者: Julia Coverdale


領域: 医学
審稿時間: 0.0 month(s)
結果: 待定&不明


撰寫評論

2023-10-28 14:52:39 評論於
How can I find the magazine's homepage?
(0) 讚! | Julia Coverdale

作者: 是志丹吖


領域: 医学
審稿時間: 0.0 month(s)
結果: 待定&不明


撰寫評論

2023-10-28 12:59:39 評論於
The homepage is in the submission information on the left menu
(0) 讚! | 是志丹吖

作者: 金山清馨


領域: 医学
審稿時間: 0.0 month(s)
結果: 待定&不明


撰寫評論

2023-10-28 08:41:06 評論於
May I ask at which stage the status "Under Review" is currently? Is it undergoing internal review or external review?
(0) 讚! | 金山清馨

作者: 岭南睿聪


領域: 医学
審稿時間: 0.0 month(s)
結果: 待定&不明


撰寫評論

2023-10-27 22:54:03 評論於
How can I register an account?
(0) 讚! | 岭南睿聪

作者: Eric Marshall


領域: 医学
審稿時間: 0.0 month(s)
結果: 待定&不明


撰寫評論

2023-10-01 21:27:52 評論於
Review Speed: 1.0 Experience Sharing: 2
(0) 讚! | Eric Marshall

作者: 白云向阳


領域: 医学
審稿時間: 0.0 month(s)
結果: 待定&不明


撰寫評論

2023-06-16 13:00:59 評論於
Review Speed: 1.0 | Submission Hit Rate: 95.0
Research Focus: Tumor Experience Sharing: 22.10.31 submitted, received review comments on 11.30, minor revisions, given two weeks to revise, editor was very good, can apply for more time if feel it's not enough. Returned for revisions on 12.20, accepted on 12.29. Paid a publication fee of one thousand euros on 2023.1.3, online on 2.14, indexed on 4.6. Overall, it was still very fast, although it's a fourth-tier journal, the impact factor is not high, but it solved the problem of graduating
(0) 讚! | 白云向阳

作者: 火焰俊豪


領域: 医学
審稿時間: 0.0 month(s)
結果: 待定&不明


撰寫評論

2022-08-13 21:43:32 評論於
Please translate the following passage into English and Japanese, and use ":" and ":" as headings
(0) 讚! | 火焰俊豪

作者: 稻妻馨逸


領域: 医学
審稿時間: 0.0 month(s)
結果: 待定&不明


撰寫評論

2022-08-09 11:10:01 評論於
+1 Did you reject it?
(0) 讚! | 稻妻馨逸

作者: 断门星津


領域: 医学
審稿時間: 0.0 month(s)
結果: 待定&不明


撰寫評論

2022-07-08 09:51:53 評論於
Please translate the following paragraph into English and Japanese, and label them as ":" and "
(0) 讚! | 断门星津

作者: 暴风雪容


領域: 医学
審稿時間: 0.0 month(s)
結果: 待定&不明


撰寫評論

2022-06-08 17:18:35 評論於
Is there any water journal suitable for publishing articles on lncRNA clinical diagnosis?
(0) 讚! | 暴风雪容

首頁    上一頁    1    2    下一頁    末頁  (頁
/2)

開始撰寫 [Oncologie] 的評論:





Contact us

Contact us  

Your name*

Your email*

Your message*

Please fill in all fields and provide a valid email.

Security Code*